Latest Breaking News On - Thomas hungerbuehler - Page 5 : comparemela.com

Novartis Pharma AG: Novartis Scemblix demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia

Updated 48-week data from Phase III ASCEMBL trial consistent with improved major molecular response (MMR) rate of Scemblix (asciminib) vs. Bosulif (bosutinib) and lower discontinuation rate due to adverse

United statesEast hanoverIsabella zinckJeff legosThomas hungerbuehlerFloriana riccio furnariMichaelj mauroSamir shahParag mahantiJulie masowSloan simpsonAlina levchukNovartis oncology congress hubNovartis oncology communicationsNovartis us external communicationsNovartis external communications

Investegate |NOVARTIS AG CHF0 50(REGD) Announcements | NOVARTIS AG CHF0 50(REGD): Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up

United statesFrance generalIsabella zinckJeff legosThomas hungerbuehlerCatherine thieblemontSamir shahParag mahantiJulie masowSloan simpsonFiona phillipsAlina levchukNovartis kymriahAmerican society of clinical oncologyParis universityFollicular lymphoma international prognostic index

Novartis Scemblix® demonstrates sustained response rate in

Updated 48-week data from Phase III ASCEMBL trial consistent with improved major molecular response (MMR) rate of Scemblix® (asciminib) vs. Bosulif® .

United statesEast hanoverIsabella zinckJeff legosThomas hungerbuehlerFloriana riccio furnariMichaelj mauroSamir shahParag mahantiJulie masowSloan simpsonAlina levchukNovartis oncology congress hubNovartis oncology communicationsNovartis us external communicationsNovartis external communications

Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up

Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up
novartis.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from novartis.com Daily Mail and Mail on Sunday newspapers.

United statesFrance generalIsabella zinckJeff legosThomas hungerbuehlerCatherine thieblemontSamir shahParag mahantiJulie masowSloan simpsonFiona phillipsAlina levchukAmerican society of clinical oncologyParis universityFollicular lymphoma international prognostic indexNovartis oncology communications

Investegate |NOVARTIS AG CHF0 50(REGD) Announcements | NOVARTIS AG CHF0 50(REGD): Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i

United statesSan antonioNew jerseyEast hanoverIsabella zinckThomas hungerbuehlerAshley bufordSamir shahJulie masowParag mahantiSloan simpsonAlina levchukVirtual scientific programNovartis oncology communicationsNovartis us external communicationsNovartis external communications